Male Infertility - Pipeline Insight, 2024

Male Infertility - Pipeline Insight, 2024

DelveInsight’s, “Male Infertility - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Male Infertility pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Male Infertility Understanding

Male Infertility: Overview

Infertility is usually defined as the inability of a couple to conceive even after one year of unprotected, frequent sexual intercourse. It affects about 15% of all couples in the United States and at least 180 million worldwide. Male infertility is defined as the inability of a male to make a fertile female pregnant, also for a minimum of at least one year of unprotected intercourse. The male is solely responsible for about 20% and is a contributing factor in another 30% to 40% of all infertility cases. As male and female causes often co-exist, it is important that both partners are investigated for infertility and managed together. Overall, the male factor is substantially contributory in about 50% of all cases of infertility. There are several reasons for male fertility to occur, including both reversible and irreversible conditions. Other factors that could influence each of the partners could be their age, medications, surgical history, exposure to environmental toxins, genetic problems, and systemic diseases. The key purpose for evaluating a male for infertility is to identify his contributing factors, offer treatment for those that are reversible, determine if he is a candidate for assisted reproductive techniques (ART) and offer counseling for irreversible and untreatable conditions. In rare cases, male infertility could be a herald to a more serious condition. This is an additional reason to do a comprehensive evaluation of the male partners of infertile couples; so that any significant, underlying medical conditions can be identified and treated.

""Male Infertility - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Male Infertility pipeline landscape is provided which includes the disease overview and Male Infertility treatment guidelines. The assessment part of the report embraces, in depth Male Infertility commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Male Infertility collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Male Infertility R&D. The therapies under development are focused on novel approaches to treat/improve Male Infertility.

Male Infertility Emerging Drugs Chapters

This segment of the Male Infertility report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Male Infertility Emerging Drugs

• FE 999049: Ferring Pharmaceuticals

A novel recombinant human FSH, FE 999049 expressed from a human foetal retinal cell line (PER.C6, Crucell, Leiden, The Netherlands) is under development by Ferring Pharmaceuticals A/S for patients undergoing COS for IVF/ICSI. FE 999049 has a lower clearance compared with an rFSH from a CHO cell line, as would be expected since FE 999049 has higher sialic acid content and is thus more similar to natural FSH in the human body. The first-in-human trial with FE 999049 was a randomised, double-blind, placebo-controlled, sequential single-dose escalation trial investigating the safety, tolerability and pharmacokinetics. A Phase II clinical trial is being evaluated to investigate whether men with idiopathic infertility (unexplained reduction of semen quality), after being treated with a daily dose of 12 µg recombinant follicle stimulating hormone (rFSH) for 6 months, can improve the chance of spontaneous pregnancy observed in their female partners in comparison to placebo (inactive treatment).

Further product details are provided in the report……..

Male Infertility: Therapeutic Assessment

This segment of the report provides insights about the different Male Infertility drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Male Infertility

There are approx. 5+ key companies which are developing the therapies for Male Infertility. The companies which have their Male Infertility drug candidates in the most advanced stage, i.e. phase II include, Ferring Pharmaceuticals.

• Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Male Infertility pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Male Infertility: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Male Infertility therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Male Infertility drugs.

Male Infertility Report Insights

• Male Infertility Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Male Infertility Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Male Infertility drugs?
• How many Male Infertility drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Male Infertility?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Male Infertility therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Male Infertility and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ferring Pharmaceuticals
• Conduit Pharma
• APRILBIO co., Ltd.
• Prokrea
• Igyxos, Inc.
• Mereo Biopharma Group

Key Products

• FE 999049
• APBR2
• AZD5904
• PKB-171
• IGX12
• Leflutrozole